Agree 100%. SK and crew have stated that the reason they can't get institutional investment is because of the capital structure. Another key investment criteria is mgmt structure. The current board has zero biotech experience and has experience with shady pipes and penny stocks. And even worse is that they are all tied together through ES. SK has zero deal making experience unless you count the DIOS deal (very shady) and Affitech which is like kissing your sister. How will SK correct this problem when you stated quite well that he is ES's Biotch?
The sad part is that mgmt and the BOD own very little shares. I would bet there are 20 posters on this board that own three times or more the shares mgmt own. If things don't change soon, shareholders need to get together and make sure mgmt listens. And independent director with biotech experience would be a first step. My guess is ES would fight it. Sorry but we need accountability.